versus host disease and pulmonary damage, limit the widespread exploitation of bone marrow transplantation. 24 Graft versus host disease is thought to result because donor T lymphocytes recognise the recipient's tissues as foreign and, by mounting an immune response, damage them. In the first 100 days acute graft versus host disease presents as a rash, often accompanied by evidence of damage to the gut and liver, in 25-75% of patients.5 6 Later, chronic graft versus host disease may present by mimicking multiorgan autoimmune disease with rash, oral and ophthalmic sicca syndrome, hepatic damage, immune deficiency, and opportunistic infections.7 8 Total body irradiation with doses of the order of 10 Gy (1000 rads) is used to condition patients for bone marrow transplantation. In animal studies radiation of this order is associated with increased vascular permeability, alveolar wall oedema, and alveolar protein leak, with gross loss of lung surfactant. Seven to 28 days after irradiation alveolar macrophages become reduced in number, pneumocytes degenerate, and hyaline membranes form. Several months later cellular hyperplasia and fibrosis develop.30 Attempts to minimise radiation damage have centred on fractionating the treatment and using low dose rates. High dose pulmonary irradiation results in considerably reduced diffusing capacity for the first three months followed by possible minor improvements over a couple of years." 1525 When cytotoxic chemotherapy has not been used, as with some solid tumours, radiation to the lungs is rarely associated with appreciable changes in lung volume, forced vital capacity (FVC), forced expiratory volume in one minute (FEV1) or the FEV,/VC ratio.3' But in the long term survivors of bone marrow transplantation who have been conditioned with high dose chemotherapy and irradiation restrictive and obstructive lung disease is being described (see below).
In studying the effect upon pulmonary morbidity of allotransplantation between histocompatible siblings and even unrelated donors it will be important to take into account the experience being gained by using conditioning regimens in which irradiation is replaced by additional chemotherapy. Moreover, the long term effects of these pulmonary infections are unknown.
Unlike interstitial pneumonitis in the acquired immunodeficiency syndrome associated with HTLV III virus, only 4% of interstitial pneumonitis in immunocompromised recipients of bone marrow grafts is due to Pneumocytis carini9 10: the characteristic ground glass appearance on the chest radiograph occurring in the presence of rapidly increasing hypoxia but few auscultatory findings has become rare with the use of prophylactic co-trimoxazole. Recently Legionella pneumophila,42 Chlamydia,43 and Mycoplasma pneumonias have been reported as causes of interstitial pneumonitis. Because of poor antibody responses in these patients open lung biopsy and sophisticated culture techniques are required for definitive diagnosis, but empirical treatment with erythromycin may be warranted.
The time of onset of an interstitial pneumonitis after bone marrow transplantation has diagnostic importance. In the first two weeks few episodes are found to have an infective cause while most interstitial pneumonitis occurring after 100 days is due to treatable infective causes44: pneumocystis with cotrimoxazole and varicella virus with acyclovir. 45 Idiopathic interstitial pneumonitis accounts for up to half of all cases reported and is likely to be due to combined drug and radiation toxicity.91- 5 The International Bone Marrow Transplant Registry reports idiopathic interstitial pneumonitis to be more frequent in older patients, who have a long interval between primary diagnosis and transplantation, and who are then treated with cyclosporin and develop graft versus host disease. Low performance status before transplantation is also a risk factor.9 In the Seattle patients radiotherapy seems to be implicated, a lower incidence of pneumonitis being seen when up 500 to eight equal fractions, to a total of 12-15 Gy (1200-1500 rads) overall are delivered as opposed to a single dose of 10 Gy. In the larger registry series such discriminants were not evident, but high radiation dose rates in patients receiving methotrexate seem to be harmful.9 PULMONARY EMBOLISM During marrow harvest fat and bone fragments will inevitably be collected and subsequently infused. Transient hypoxia may occur but no long term parenchymal damage seems to ensue.4647 Nevertheless abnormalities of pulmonary vasculature are being recognised with endothelial changes and intimal thickening predisposing to thrombosis of the arterioles, capillaries, and venules that presumably reflects radiation damage.14 Pulmonary venoocclusive disease may masquerade as interstitial pneumonitis48 and, intriguingly, fat embolisation has been seen as a late complication of bone marrow transplantation.49
RESTRICTIVE AND OBSTRUCTIVE LUNG DISEASE
Among the later complications of bone marrow transplantation restrictive and obstructive defects of ventilatory function have been reported in subjects who have had pretransplantation conditioning with high dose chemotherapy and irradiation. In over 300 patients with marrow transplants studied in Seattle a mean loss of 0.81 litres of total lung capacity, 0.541 of vital capacity, and 4.4 ml/min/mm Hg of diffusing capacity (1.5 mmol min-1 kPa-' of transfer factor) was evident one year after transplantation.' 5 In most patients these changes improved over the next three to four years. Obstructive lung disease seems to become more prominent with the passage of time. Reduction in FEV1/VC to less than 50%, 60%, and 70% predicted was seen in 0%, 2%, and 11% at three months but in 8%, 18%, and 29% by three years. Unfortunately the pathological findings in patients reported in this study are unknown. What is causing such lung damage remains something of an enigma, since severe obstruction was not attributable in this series to previous whole body irradiation, interstitial pneumonitis, or chronic graft versus host disease.
GRAFT VERSUS HOST DISEASE AND BRONCHIOLITIS OBLITERANS
The relationship between graft versus host disease and the lung remains uncertain. Although several pulmonary entities have been linked with graft versus host disease, definite evidence that these are true manifestations of graft versus host disease is lacking. Lymphocytic bronchitis with the histological demonstration of lymphocytic infiltration of the bronchial mucosa, loss of cilia and goblet cells, and even necrosis of mucosa and submucosa has been described as a postmortem finding in 25% of patients dying after bone marrow transplantation,50 many patients having had cough and dyspnoea. Recent studies suggest that these findings relate poorly if at all to the presence of graft versus host disease and are probably due to earlier chemotherapy.5' Lymphocytic interstitial pneumonitis has also been reported as a late complication of bone marrow transplantation,52 but the relationship of such an entity to graft versus host disease is uncertain and further studies of the lungs of patients with no other evidence of graft versus host disease are needed. In 1982 the first cases of severe irreversible airways obstruction occurring within five months of bone marrow transplantation and in the context of chronic graft versus host disease were reported. 53 The chest radiograph may be normal, but hyperinflation flat diaphragms and pneumothoraces have been reported, in association with reduced elastic recoil pressure. Histological appearances are those of bronchiolitis obliterans. The clinical course is variable. Treatment with corticosteroids and azathioprine may be of benefit, although the mortality rate remains high.53-58 Workers in one centre contend that as many as 13% of all recipients of marrow grafts have this complication.54 Its aetiology may be multifactorial, and it may not necessarily be directly attributable to graft versus host disease itself but may result from recurrent infection or recurrent gastrooesophageal regurgitation. Others contend that it is related to the fibrotic chronic mucositis of the mouth and oesophagus seen in many cases of chronic graft versus host disease.
The contributions, if any, of graft versus host disease and its prophylaxis to pulmonary sequelae after BMT may become clearer by studying the patient who has received an autotransplant. Here marrow is harvested from the patient himself, preserved, and reinfused after intensive chemotherapy or radiation therapy (or both) has been used to control resistant disease. The patient is rescued from bone marrow failure by his own marrow. Such treatment is of potential use in the treatment of solid tumours and is being explored in haematological malignancies, particularly where resistant disease is present in sanctuary sites.
The seriousness of pulmonary damage to patients who have bone marrow transplantation must not be underestimated. Many further studies are needed. Sufficient numbers of patients with similar underlying disorders must be studied. Investigations must detail pretransplant pulmonary function, previous infections, chemotherapy, radiotherapy, transfusions, and smoking history. Sequential assessment of pulmonary function must be performed in relation to clinical events and combined with detailed bacteriological and virological monitoring. Episodes of graft versus host disease need to be defined in terms of biopsy changes in relevant tissues. Many more reports of lung biopsy material studied by histological and immunohistochemical means are needed in conjunction with evidence of intensive search for infective organisms, particularly viruses. In this way the causes of pulmonary morbidity may be determined more precisely and the way prepared for prevention and the realisation of the wider application of bone marrow transplantation.
